Table 1.
Demographic and clinical characteristics
| Azacitidine (n = 288) | Decitabine (n = 199) | p-value | |
|---|---|---|---|
|
Demographic characteristics | |||
| Age, mean (SD) |
70.3 years (11.8) |
69.4 years (11.6) |
0.3890 |
| 18-64 years old |
25.3 |
28.6 |
-- |
| 65+ years old |
74.7 |
71.4 |
-- |
| Gender (% male) |
59.0 |
54.8 |
0.3510 |
| Insurance Type |
|
|
0.2450 |
| Commercial Insurance (%) |
46.5 |
41.2 |
-- |
| Medicare Advantage (%) |
53.5 |
58.8 |
-- |
|
Clinical characteristics | |||
| MDS diagnosis *, % |
54.5 |
51.9 |
0.549 |
| RBC transfusion*, % |
51.0 |
54.8 |
0.4185 |
| ESA utilization** |
26.4 |
25.1 |
0.754 |
| G/GM-CSF utilization** |
18.1 |
19.1 |
0.771 |
| Charlson Comorbidity Index* mean (SD) |
3.0 (1.7) |
3.4 (1.8) |
0.0140 |
| Hospitalization* | 61.5 | 70.9 | 0.0323 |
*baseline period, 6 months pre-index.
**follow-up period, post-index.